• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为颌骨坏死危险因素的、对血管生成抑制有影响的疾病。

Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw.

作者信息

Paek Seung Jae, Park Won-Jong, Shin Ho-Sung, Choi Moon-Gi, Kwon Kyung-Hwan, Choi Eun Joo

机构信息

Department of Oral and Maxillofacial Surgery, Wonkwang University Dental Hospital, Wonkwang University, Iksan, Korea.

Department of Oral and Maxillofacial Surgery, College of Dentistry, Wonkwang University, Iksan, Korea.

出版信息

J Korean Assoc Oral Maxillofac Surg. 2016 Oct;42(5):271-277. doi: 10.5125/jkaoms.2016.42.5.271. Epub 2016 Oct 25.

DOI:10.5125/jkaoms.2016.42.5.271
PMID:27847735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5104869/
Abstract

OBJECTIVES

The objective of this study was to retrospectively investigate the association of diseases having an influence on inhibition of angiogenesis such as hypertension, diabetes mellitus type II, hypercholesterolemia, and rheumatoid arthritis (RA) with the development of osteonecrosis of the jaws.

MATERIALS AND METHODS

The 135 patients were allocated into 4 groups of bisphosphonate-related osteonecrosis of the jaw (BRONJ) group (1A); non-BRONJ group (1B); osteonecrosis of the jaw (ONJ) group (2A); and control group (2B), according to histologic results and use of bisphosphonate. This retrospective study was conducted with patients who were treated in one institute from 2012 to 2013. Fisher's exact test and logistic regression analysis were used to analyze the odds ratios of diseases having an influence on inhibition of angiogenesis for development of ONJ.

RESULTS

The effects of diabetes and hypertension were not statistically significant on development of ONJ. When not considering bisphosphonate use, RA exhibited a high odds ratio of 3.23 (=0.094), while hyperlipidemia showed an odds ratio of 2.10 (=0.144) for development of ONJ. More than one disease that had an influence on inhibition of angiogenesis showed a statistically significant odds ratio of 2.54 (=0.012) for development of ONJ.

CONCLUSION

Patients without diseases having an influence on inhibition of angiogenesis were at less risk for developing ONJ.

摘要

目的

本研究的目的是回顾性调查高血压、II型糖尿病、高胆固醇血症和类风湿性关节炎(RA)等影响血管生成抑制的疾病与颌骨坏死发生之间的关联。

材料与方法

根据组织学结果和双膦酸盐的使用情况,将135例患者分为4组:双膦酸盐相关颌骨坏死(BRONJ)组(1A);非BRONJ组(1B);颌骨坏死(ONJ)组(2A);以及对照组(2B)。本回顾性研究针对2012年至2013年在一家机构接受治疗的患者进行。采用Fisher精确检验和逻辑回归分析来分析影响血管生成抑制的疾病对ONJ发生的比值比。

结果

糖尿病和高血压对ONJ发生的影响无统计学意义。在不考虑双膦酸盐使用的情况下,RA发生ONJ的比值比为3.23(=0.094),而高脂血症的比值比为2.10(=0.144)。一种以上影响血管生成抑制的疾病发生ONJ的比值比为2.54(=0.012),具有统计学意义。

结论

没有影响血管生成抑制疾病的患者发生ONJ的风险较低。

相似文献

1
Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw.作为颌骨坏死危险因素的、对血管生成抑制有影响的疾病。
J Korean Assoc Oral Maxillofac Surg. 2016 Oct;42(5):271-277. doi: 10.5125/jkaoms.2016.42.5.271. Epub 2016 Oct 25.
2
Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.抗骨吸收(靶向骨)药物之外的颌骨骨坏死:肿瘤学的新视野
Expert Opin Drug Saf. 2016 Jul;15(7):925-35. doi: 10.1080/14740338.2016.1177021. Epub 2016 May 3.
3
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.静脉注射双膦酸盐相关颌骨坏死:骨闪烁显像作为早期指标
J Oral Maxillofac Surg. 2009 Jul;67(7):1363-72. doi: 10.1016/j.joms.2009.03.005.
4
Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.接受骨靶向治疗患者的颌骨骨坏死:概述——第一部分
Urol Nurs. 2016 May-Jun;36(3):111-6, 154.
5
Biomarkers for Bisphosphonate-Related Osteonecrosis of the Jaw.双膦酸盐相关颌骨坏死的生物标志物
Clin Implant Dent Relat Res. 2016 Apr;18(2):281-91. doi: 10.1111/cid.12297. Epub 2015 Feb 26.
6
Osteonecrosis of the jaw and nonmalignant disease: is there an association with rheumatoid arthritis?颌骨骨坏死与非恶性疾病:与类风湿关节炎有关吗?
J Rheumatol. 2013 Jun;40(6):781-6. doi: 10.3899/jrheum.120810. Epub 2013 Mar 15.
7
Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.当前对颌骨骨坏死病理生理学的认识。
Curr Osteoporos Rep. 2018 Oct;16(5):584-595. doi: 10.1007/s11914-018-0474-4.
8
The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan.台湾地区双膦酸盐相关颌骨坏死的全国性队列研究。
J Dent. 2014 Oct;42(10):1343-52. doi: 10.1016/j.jdent.2014.05.001. Epub 2014 Jun 4.
9
Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview.颌骨药物相关性骨坏死发展中的血管生成:综述
Dent J (Basel). 2016 Dec 26;5(1):2. doi: 10.3390/dj5010002.
10
Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw.微裂纹在双膦酸盐相关颌骨坏死发病机制中的作用。
Clin Oral Investig. 2016 Nov;20(8):2251-2258. doi: 10.1007/s00784-016-1718-2. Epub 2016 Jan 22.

引用本文的文献

1
Clinical Effectiveness of Surgical Marginal Resection with Piezoelectric Device on Bisphosphonate-Related Osteonecrosis of the Jaws: A Retrospective Study.使用压电装置进行手术边缘切除治疗双膦酸盐相关颌骨骨坏死的临床疗效:一项回顾性研究。
J Clin Med. 2025 May 28;14(11):3792. doi: 10.3390/jcm14113792.
2
A case series and review of canine idiopathic osteonecrosis of the jaw.犬颌骨特发性骨坏死的病例系列及综述
Front Vet Sci. 2025 May 27;12:1614645. doi: 10.3389/fvets.2025.1614645. eCollection 2025.
3
The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists.预防药物相关性颌骨坏死(MRONJ):意大利专家为口腔卫生师制定的立场文件。
Support Care Cancer. 2022 Aug;30(8):6429-6440. doi: 10.1007/s00520-022-06940-8. Epub 2022 Mar 16.
4
Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw.局部递送水凝胶包封的血管内皮生长因子预防药物相关性颌骨坏死。
Sci Rep. 2021 Dec 3;11(1):23371. doi: 10.1038/s41598-021-02637-w.
5
The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review.抗吸收药物与颌骨药物相关性骨坏死在非肿瘤性免疫抑制患者中的作用:一项系统评价
J Res Med Sci. 2021 Mar 31;26:23. doi: 10.4103/jrms.JRMS_794_20. eCollection 2021.
6
Refractory healing after surgical therapy of osteonecrosis of the jaw: associated risk factors in aged patients.颌骨骨坏死手术后治疗后难治性愈合:老年患者的相关危险因素。
Clin Interv Aging. 2019 May 6;14:797-804. doi: 10.2147/CIA.S200455. eCollection 2019.
7
Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries.亚洲国家骨质疏松症患者中抗吸收剂相关的颌骨坏死
Osteoporos Sarcopenia. 2017 Jun;3(2):64-74. doi: 10.1016/j.afos.2017.03.001. Epub 2017 Mar 21.
8
Panoramic radiographic features that predict the development of bisphosphonate-related osteonecrosis of the jaw.全景 X 线片特征预测双膦酸盐相关性颌骨骨坏死的发生。
Oral Radiol. 2018 May;34(2):151-160. doi: 10.1007/s11282-017-0293-9. Epub 2017 Jun 12.

本文引用的文献

1
American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.美国口腔颌面外科医师协会关于药物相关性颌骨坏死的立场文件——2014年更新版
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. doi: 10.1016/j.joms.2014.04.031. Epub 2014 May 5.
2
Diabetes microvascular disease and the risk for bisphosphonate-related osteonecrosis of the jaw: a single center study.糖尿病微血管病变与双膦酸盐相关性颌骨骨坏死风险:一项单中心研究。
J Clin Endocrinol Metab. 2013 Nov;98(11):E1807-12. doi: 10.1210/jc.2013-2434. Epub 2013 Sep 13.
3
Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.考虑原发性疾病和伴随治疗时双膦酸盐相关性颌骨骨坏死的发生率。
Anticancer Res. 2013 Sep;33(9):3917-24.
4
Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches.糖尿病相关血管损伤:新型循环生物标志物和治疗方法。
J Am Coll Cardiol. 2013 Aug 20;62(8):667-76. doi: 10.1016/j.jacc.2013.03.089.
5
Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay.双膦酸盐在双膦酸盐相关颌骨坏死发生发展中的抗血管生成潜能:对体内三维基质胶试验中微血管芽生的影响
Clin Oral Investig. 2014 Apr;18(3):1015-22. doi: 10.1007/s00784-013-1060-x. Epub 2013 Jul 28.
6
Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: a study in Wistar rats.糖尿病和皮质激素治疗作为导致阿仑膦酸钠相关性颌骨坏死的危险因素:一项 Wistar 大鼠研究。
Head Neck. 2014 Jan;36(1):84-93. doi: 10.1002/hed.23260. Epub 2013 May 4.
7
Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw.血清 VEGF 水平作为预测双膦酸盐相关性下颌骨坏死的标志物。
J Hematol Oncol. 2012 Sep 17;5:56. doi: 10.1186/1756-8722-5-56.
8
Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing.内皮功能障碍与糖尿病:对血管生成、血管重塑和伤口愈合的影响。
Int J Vasc Med. 2012;2012:918267. doi: 10.1155/2012/918267. Epub 2012 Feb 12.
9
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.从实验室到临床:OPG-RANK-RANKL 通路的阐明和地舒单抗的研发。
Nat Rev Drug Discov. 2012 May;11(5):401-19. doi: 10.1038/nrd3705.
10
Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws.类风湿关节炎患者口腔双膦酸盐相关性颌骨骨坏死的流行病学方面。
Head Face Med. 2012 Mar 1;8:5. doi: 10.1186/1746-160X-8-5.